Mesulid (Nimesulide)

Nimesulide works by selectively inhibiting the cyclooxygenase‑2 (COX‑2) enzyme, which lowers the production of prostaglandins that cause pain, fever, and inflammation. This selective action helps provide analgesic and anti‑inflammatory effects while sparing COX‑1 activity that protects the stomach lining.

The appropriate dose of Mesulid is determined by the prescribing healthcare professional based on the patient’s condition, age, weight, and response to therapy. Dosage regimens may vary, and patients should follow the specific instructions given by their prescriber.

Safety data for nimesulide in pregnancy and lactation are limited. It is generally advised to avoid using Mesulid during pregnancy, especially in the third trimester, and while breastfeeding unless the benefits clearly outweigh the potential risks as assessed by a qualified clinician.

To order Mesulid, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mesulid (nimesulide) is a selective COX‑2 inhibitor, whereas ibuprofen is a non‑selective NSAID that blocks both COX‑1 and COX‑2. This selectivity may reduce the risk of gastrointestinal irritation compared with ibuprofen, but both share similar analgesic and anti‑inflammatory properties and carry comparable risks of liver and renal effects.

Mesulid should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid using it after the expiry date indicated on the label.

Mesulid is taken orally, usually with a full glass of water. It can be taken with food or a light meal to lessen possible stomach discomfort. Patients should swallow the tablet whole and not split, crush, or chew it unless specifically instructed by a healthcare professional.

The most serious risks associated with Mesulid include liver injury (hepatotoxicity), severe skin reactions such as Stevens‑Johnson syndrome, gastrointestinal bleeding or ulceration, and acute renal failure. Patients should seek immediate medical attention if they notice symptoms like jaundice, rash, vomiting blood, or sudden decrease in urine output.

Mesulid should be avoided in individuals with known hypersensitivity to nimesulide or other NSAIDs, those with active peptic ulcer disease, severe liver or kidney impairment, and patients who are currently taking anticoagulants, other NSAIDs, or corticosteroids without medical supervision. Pregnant women, especially in the third trimester, should also refrain from using it unless directed by a physician.